Pacific Bio, yet another contender for the $1,000 genome
More than a half-dozen startups and established companies are in hot pursuit of the “$1,000 genome,” a Holy Grail for those who believe fast, cheap genome sequencing will revolutionize medicine. The latest is Pacific Biosciences, a formerly secretive Menlo Park, Calif., company that just spilled its guts to the NYT over the weekend. We take a look at the company, its technology and the competitive landscape in this piece over at VentureBeat Life Sciences.
Next Story: Nokia launches ad network, several major publishers already on board
Previous Story: Yahoo rejects Microsoft’s proposal, more money or new offers welcome
About the Author, David P. Hamilton
David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.